nRollmed accelerated patient recruitment, helping the sponsor beat out market competitors to reach commercialization sooner than anticipated.
Finding people with NASH is challenging as patients are often undiagnosed and are often unaware of disease implications, including liver failure and liver cancer.
nRollmed targeted only those with common, relevant risk factors. A scoring system was developed to assess a candidate’s likelihood of suffering from NASH. A detailed discussion about the potential need for a biopsy was discussed, which saved the sites valuable time.
underwent biopsies, resulting in 4 randomized patients
nRollmed performed at more than two times the NASH industry standard.